Nuvalent, Inc.
NASDAQ:NUVL
84.22 (USD) • At close December 20, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Nuvalent, Inc. |
Symbool | NUVL |
Munteenheid | USD |
Prijs | 84.22 |
Beurswaarde | 5,984,046,182 |
Dividendpercentage | 0% |
52-weken bereik | 61.795 - 113.51 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. James R. Porter Ph.D. |
Website | https://www.nuvalent.com |
An error occurred while fetching data.
Over Nuvalent, Inc.
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)